RBC Capital analyst Brian Abrahams maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) yesterday and set a price target of $65.00. The company’s shares closed yesterday ...
H.C. Wainwright lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $50 from $75 and keeps a Buy rating on the shares. The firm believes “consistent updates” from Corbus on ...
March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, today provided a ...
NORWOOD, Mass. (AP) — NORWOOD, Mass. (AP) — Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based ...
NORWOOD, Mass. (AP) — NORWOOD, Mass. (AP) — Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based company said ...
NORWOOD, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity ...
City spokeswoman Melinda Stotts confirmed Landon Cole Corbus, 28, of Quapaw, resigned February 28. Corbus is charged in Lawrence County 39th Judicial Circuit Court with theft and third-degree ...
March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback